Condition: Non-Hodgkin Lymphoma · Multiple Myeloma · Histiocytic Neoplasms · Sponsor: Memorial Sloan Kettering Cancer Center
The purpose of this study is to determine the uptake of the imaging agent \[68Ga\]-pentixafor with PET/CT scans in people with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and non-Hodgkin lymphoma (NHL), or you have histiocytic neoplasms (Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD) and/or Rosai-Dorfman disease (RDD).
This description comes directly from the study's public registry record.
Anton Nosov, MD · 212-639-8575 · nosova@mskcc.org
Heiko Schoder, MD · 212-639-2079
Always discuss trial participation with your own doctor first.
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05093335